People report a side effect, hear nothing, and reasonably conclude the report went nowhere. What actually happens is that no individual report is meant to produce an individual answer - the system works by accumulating reports until a pattern emerges that is stronger than coincidence. Understanding that makes the silence less discouraging, and explains why reporting an uncertain suspicion is useful rather than a waste of anyone's time.
Where it goes
Reports go to the MHRA and into a national database, alongside reports from health professionals, coroners and manufacturers.
They are combined with data from other countries, since regulators share safety information internationally.
Manufacturers are legally required to submit reports they receive and to review their own safety data periodically.
Signal detection
The analytical question is not "did this medicine cause this event" but "does this event occur more often after this medicine than would be expected".
Because medicines are taken by very large numbers of people, many of whom are unwell for unrelated reasons, a proportion of reported events would have happened anyway.
So the raw count tells you little. What matters is the comparison against background rates, adjusted for how many people take the drug.
When a disproportion appears, that is a signal - a hypothesis to investigate, not a conclusion.
What investigation involves
A signal is assessed against everything else available: clinical trial data, published studies, prescribing databases, the biological plausibility of a mechanism, and what happened when people stopped and restarted the drug.
Expert committees advise on the result.
The possible outcomes range widely:
- No action - the pattern is explained by something else
- A change to the product information, adding a side effect or a caution
- New warnings to prescribers
- Restrictions on who may take it or how it may be used
- New monitoring requirements
- Suspension or withdrawal, which is rare
Restrictions are far more common than withdrawal - the JAK inhibitor age and smoking restrictions, the montelukast mood warnings and the valproate pregnancy programme are all examples.
See when a medicine is withdrawn for safety.
How you would find out
You will not usually be contacted about your own report, though you may be asked for more detail.
What is public:
Drug Safety Update, published monthly by the MHRA, is where new warnings and restrictions are announced. It is freely readable.
Interactive Drug Analysis Profiles publish the anonymised Yellow Card data for individual medicines, so you can see what has been reported. Worth approaching carefully - a long list of reported events is not a list of proven effects.
The patient information leaflet is updated when product information changes, which is why leaflets grow over time.
See reading the patient information leaflet.
Why uncertain reports still count
The threshold is suspicion, deliberately, because requiring certainty would filter out exactly the reports that reveal something new.
The first reports of any genuinely novel side effect are made by people who are unsure.
Under-reporting is the system's main limitation, and it is worst for older medicines, for older people, for children and for off-label use - the situations where evidence is already thinnest.
See side effects in older people and off-label and unlicensed prescribing.
Black triangle medicines
An inverted black triangle on the packaging means the medicine is under additional monitoring, and that all suspected reactions should be reported rather than only unexpected ones.
It is not a warning about the medicine - it usually means it is newer, so the safety picture is still filling in.
What reporting does not do
It is not a complaint, and it is not a claim.
If you believe you have been harmed and want that addressed, that is a separate route - a complaint to the provider, or advice about compensation schemes.
Reporting does not start either process, and making a claim does not substitute for reporting.
See if a medicine has harmed you.
How long it takes
The honest answer is months to years, and occasionally longer.
A single report rarely changes anything on its own; a cluster investigated over a year or two might. Where a signal is serious enough, regulators can act quickly and issue an urgent alert, but that is the exception. Knowing the timescale is the difference between concluding that nothing happened and understanding that the process is simply slow.
Meanwhile, tell your prescriber
The Yellow Card system works on a timescale of months and years. Your own care does not.
Report to the MHRA and tell whoever prescribes for you, because the immediate decision - change the dose, switch, stop, investigate - is made locally.
See medication reviews.
The Side Effects section covers more on side effects and safety - How the Yellow Card Scheme Works is closely related to this one.